Purpose {#sec1}
=======

The concept of oligo-metastasis \[[@cit0001]\] based on surgical studies \[[@cit0002],[@cit0003],[@cit0004]\] that was discussed for the first time in the 1990s, differs from the rigid scheme of palliation vs. curation. There is a cohort of oligo-metastasized patients, which is not yet clearly definable that benefits from a consequent local ablation in terms of an improvement in the overall prognosis \[[@cit0005]\]. The gold standard of local treatment is surgical procedure \[[@cit0006]\]. However, since a high proportion of hepatic oligo-metastases is not resectable, alternative ablation procedures have been successfully tested \[[@cit0007]\]. The "toolbox of ablative treatments" is now a part of the current "ESMO (European Society for Medical Oncology) guidelines for the management of patients with metastatic colorectal cancer" \[[@cit0008]\].

In this study, radio-ablative methods are particularly investigated.

The development of high-performance software for calculation and application of prescribed irradiation dose and device-based hardware, currently allow for very precise implementation of hypo-fractionated and radio-surgical approaches \[[@cit0009],[@cit0010]\]. Therefore, in no resectable patient, primary and secondary liver malignancies can often be treated very effectively with radiotherapy \[[@cit0011]\]. The key for effective and sustainable radio-ablation is to provide adequate clinical target volume doses \[[@cit0012],[@cit0013]\], taking into account the dose limits of adjacent organs at risk (OARs). Particularly, in the case of marginal liver tumor, compromises cannot often be avoided at the expense of a potentially reduced chance of local control.

The aim of the present analysis was to investigate the feasibility and safety of a novel approach, in particular, to examine whether an increase in the distance between the target volume and the structure at risk is technically possible without severe complications and to what extent a dosimetric advantage is generated.

Material and methods {#sec2}
====================

Patients {#sec2.1}
--------

As a rule, all patients who might be eligible for brachytherapy of the liver are considered by a tumor board prior to the initial presentation at our department. A standard operating procedure (SOP) defines the inclusion and exclusion criteria for performing interstitial brachytherapy (iBT) of the liver. All patients sign a written informed consent prior to planning a computed tomography (CT)- or magnet resonance imaging (MRI)-guided interstitial brachytherapy. From April 2009 to June 2016, 2,082 patients with primary or secondary liver tumors were treated with interstitial high-dose-rate (HDR) brachytherapy; 137 cases (6.6%) had subcapsular liver tumors near the stomach, duodenum, or large intestine (OAR).

From this cohort, 31 patients were included in the study and received one or two additional balloon catheter(s) to increase the distance between the hepatic margin/surface and adjacent OAR, as part of single stage CT-guided iBT (recorded dose-volume histogram (DVH) parameters, [Table 1](#t0001){ref-type="table"} and [Figure 1](#f0001){ref-type="fig"}).

###### 

Recorded dose-volume histogram (DVH) parameters

  Patient study number   Prescribed single-dose for D~100~ CTV (Gy)   Calculated dose for D~100~ CTV with balloon (Gy)   Adjacent OAR      Accepted calculated dose for OAR D1~cc~ with balloon (Gy)   Calculated dose for anticipated OAR without balloon
  ---------------------- -------------------------------------------- -------------------------------------------------- ----------------- ----------------------------------------------------------- -----------------------------------------------------
  1                      20                                           10.560                                             Stomach           15.720                                                      16.195
  2                      12                                           6.700                                              Stomach           13.500                                                      21.798
  3                      15                                           7.740                                              Duodenum          12.250                                                      12.420
  4                      20                                           8.750                                              Stomach           14.250                                                      15.610
  5                      20                                           9.330                                              Stomach           13.938                                                      16.501
  6                      15                                           15.117                                             Large intestine   16.540                                                      25.130
  7                      20                                           11.010                                             Stomach           13.880                                                      14.440
  8                      15                                           14.250                                             Stomach           12.980                                                      15.460
  9                      20                                           20.300                                             Stomach           9.320                                                       13.924
  10                     15                                           12.050                                             Stomach           14.010                                                      15.456
  11                     20                                           20.580                                             Duodenum          13.510                                                      16.160
  12                     20                                           20.930                                             Stomach           14.220                                                      15.625
  13                     20                                           20.670                                             Stomach           11.390                                                      14.310
  14                     20                                           20.830                                             Stomach           13.560                                                      14.290
  15                     20                                           15.886                                             Stomach           14.350                                                      15.964
  16                     15                                           15.130                                             Stomach           8.970                                                       21.030
  17                     12                                           12.310                                             Stomach           11.290                                                      13.390
  18                     15                                           15.240                                             Stomach           14.280                                                      23.787
  19                     15                                           13.140                                             Stomach           11.160                                                      13.910
  20                     20                                           20.827                                             Stomach           9.200                                                       11.130
  21                     20                                           15.440                                             Stomach           12.310                                                      14.700
  22                     15                                           9.940                                              Stomach           13.685                                                      14.957
  23                     15                                           15.146                                             Stomach           10.230                                                      13.389
  24                     25                                           27.420                                             Stomach           9.920                                                       16.870
  25                     25                                           25.300                                             Stomach           13.430                                                      17.220
  26                     20                                           15.150                                             Stomach           14.810                                                      14.920
  27                     25                                           25.290                                             Stomach           13.640                                                      17.688
  28                     20                                           20.700                                             Stomach           12.220                                                      15.497
  29                     25                                           27.560                                             Stomach           8.890                                                       18.160
  30                     15                                           13.900                                             Stomach           10.437                                                      11.300
  31                     20                                           22.530                                             Stomach           13.710                                                      15.459

Prescribed and calculated dose for D~100~-CTV, accepted calculated dose for OAR-D~1cc~ with balloon, calculated dose for OAR-D~1cc~ regarding anticipated OAR-contour without balloon.

![Tomography imaging: **A**) Transversal MRI-scan: tumor lesion with marginal enhancement of contrast media, no BT, catheter; distinctly adjacent stomach; **B**) Corresponding transversal CT-scan with stomach position without balloon; one BT, catheter inserted; **C**) Corresponding transversal CT-scan; CTV and stomach contoured; **D**) Corresponding transversal CT-scan with additional balloon; CTV, stomach and stomach, virtual position without balloon contoured](JCB-11-36507-g001){#f0001}

The prescribed dose related to D~100~ depends on the histology of the primary tumor lesion (GIST \[gastrointestinal stromal tumor\] = 12 Gy, breast cancer, renal cell carcinoma, hepatocellular carcinoma = 15 Gy, other histologies = 20 Gy). The dose was applied as a single fraction targeted on the complete tumor ablation.

Method {#sec2.2}
------

Methodology and course of single-dose interstitial HDR brachytherapy was already described in detail elsewhere \[[@cit0012],[@cit0014]\].

Briefly, HDR-brachytherapy catheters (Primed, Halberstadt, Germany) and angiographic occlusion balloon catheters (Equalizer^TM^ Occlusion Balloon Catheter, 20 and 27 mm, Boston Scientific, Marlborough, USA) were placed in a similar way using CT fluoroscopy (Aquilion Prime, Canon Medical Systems, Neuss, Germany). Following the puncture of the target lesion (for brachytherapy catheters) or between the liver capsule with the adjacent target lesion and the OAR (for balloon catheters) with an 18-G coaxial needle, a stiff angiography wire (Amplatz Super Stiff^TM^, Boston Scientific, Boston, MA, USA) was introduced for placement of a 6 F (for brachytherapy catheters) or 12 F (for balloon catheters) introducer sheath (Radifocus^®^, Terumo, Tokyo, Japan), using the Seldinger technique, through which the brachytherapy or balloon catheter was inserted. When in the correct position, the balloon catheter was inflated (with contrast medium) to dissociate the OAR from the target volume ([Figure 2](#f0002){ref-type="fig"}). After placement of brachytherapy and balloon catheters, a contrast agent-enhanced (intravenously, iodine-based, 80 ml) spiral CT in breath-holding-technique (slice thickness, 3 mm) of the liver was acquired. The catheter position, the tumor margin, and anatomic risk structures verified by contrast-enhanced images were sent to the treatment planning unit (Oncentra Brachy, Elekta AB, Stockholm, Sweden).

![Planning transversal CT scan with isodoses, prescribed dose to D100 CTV 20 Gy: **A**) CT-scan without balloon, one BT-catheter inserted; **B**) CT-scan with BT-catheter and one balloon-catheter inserted](JCB-11-36507-g002){#f0002}

The decision to insert a balloon catheter was made after the evaluation of liver specific MRI scans (slice thickness, 3 mm; MRI protocol included: T2-weighted ultra-turbo spin echo sequences with and without fat saturation, diffusion-weighted imaging, a T1-weighted gradient echo sequence, T1-weighted dynamic sequences, and sequences acquired 20 min after IV administration of 0.1 ml/kg Gd-EOB-DTPA \[Primovist^®^, Bayer Vital, Leverkusen, Germany\] performed on an 1.5-tesla MRI scanner \[Intera 1.5T, Philips Healthcare, Hamburg, Germany\], if within the framework of a virtual catheter application, the calculated clinical target volume (CTV) enclosing prescription dose (D~100~) did not seem to be feasible under consideration of the institutional OAR dose limits concerning D~1cc~ and V~5~ \[[@cit0013],[@cit0015],[@cit0016]\], and outstanding publications and reviews, inter alia, by Timmermann, Herfarth *et al*. and Sterzing *et al*. \[[@cit0017],[@cit0018],[@cit0019]\] ([Table 2](#t0002){ref-type="table"}).

###### 

Dose constraints regarding organs at risk for single dose

  Organ at risk   Timmermann SBRT constraints \[[@cit0017]\]   Herfarth, Sterzing, SBRT constraints \[[@cit0018],[@cit0019]\]   Institutional constraints due to prospective and retrospective analysis of the XX/YY study-group \[[@cit0013],[@cit0015],[@cit0016]\]                            
  --------------- -------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- --------------- -------- ------------------------------------------
  Stomach         D~10cc~                                      \< 13.0                                                          D~max~                                                                                                                                  12.0            D~1cc~   14 (15[\*](#tf2-1){ref-type="table-fn"})
  Duodenum        D~5cc~                                       \< 8.8                                                           D~max~                                                                                                                                  12.0            D~1cc~   14 (15[\*](#tf2-1){ref-type="table-fn"})
  Colon           D~20cc~                                      \< 11.0                                                          Not specified                                                                                                                           Not specified   D~1cc~   18
  Liver           D~700cc~                                     9.1                                                              D~50~                                                                                                                                   4.0-7.0         V~5~     /66

The original values based on Streitparth's work \[[@cit0013]\] were decreased to 14 Gy from 2012 to further reduce the risk of late toxicity.

The time for insertion of one balloon catheter corresponds approximately to the application time of two BT catheters (mean, 16 min). In case of an implant with one BT catheter tripling the intervention time and in case of more advanced liver lesions with 8 catheters, the duration time of the intervention increases by approximately 25%.

In addition to CTV, liver and adjacent OAR (predominantly stomach) as well as virtual OAR volume without a balloon were contoured; the virtual position of the OAR could be anticipated by assessing the pre-interventional MRI scans and additionally, with the interventional CT scans with BT catheter only ([Figure 1](#f0001){ref-type="fig"}).

Dose calculation was performed in strict accordance with institutional OAR limits ([Table 2](#t0002){ref-type="table"}). The relevant parameters for this analysis such as prescription dose, D~100~-CTV, D~1cc~-OAR with and without a balloon were recorded. The values for the D1~cc~-OAR with and D1~cc~-OAR without balloon were distinguished as two groups and statistically evaluated.

The values for D1~cc~-OAR with and D1~cc~-OAR without balloon were assigned to two groups. These two cohorts were compared statistically.

Interstitial HDR brachytherapy was performed using an ^192^Ir source with an afterloading device from Elekta (MicroSelectron HDR V3, Oncentra Brachy, Elekta AB, Stockholm, Sweden).

Statistics {#sec2.3}
----------

Statistics were collected with R (version 3.1.3; the R Foundation for Statistical Computing, Vienna, Austria).

Due to small sample size, non-parametric distribution of data was assumed, and data were described by median, interquartile range (IQR, 25^th^-75^th^ percentiles), and minimum and maximum. Boxplots were used for visualization of data. Correlation of data was analyzed with Spearman's rho rank correlation coefficient and agreement of methods was described using Bland-Altman analysis \[[@cit0020]\]. Paired groups (with/without balloon) were compared with Wilcoxon signed rank test, and optimal cut-off was determined using receiver operating characteristics (ROC) curves \[[@cit0021]\] and Youden index as appropriate. All tests were two-sided, and the significance level was set as 0.05.

Statement {#sec2.4}
---------

The study was performed according to the guidelines of the Declaration of Helsinki for Biomedical Research from 1964 and its further amendments, and the procedures of "Good Research Practice". The analysis was designed as a retrospective study with approval of the local ethics committee. Each patient signed a written consent form prior to the planned intervention after an adequate patient-physician talk on the intervention and the frequency, severity, and profile of its complications.

Results {#sec3}
=======

Patients {#sec3.1}
--------

Thirty-one patients (17 females, 14 males; median age, 65.3 \[range, 38-85\] years), 22% of those with subcapsular liver tumors, were enrolled in the study. In 25 cases, one in 6 cases, two balloon catheters were inserted.

In 74% of the patients, primary lesions outside the liver were histologically confirmed (colorectal carcinoma, 45%; others, 29%), 26% had primary liver malignancies.

The marginal hepatic lesions were located within the liver segments 2/3 in 29 cases (93.5%), 2 patients had lesions within the right hepatic lobe, near large intestine. Patients' characteristics are presented in [Table 3](#t0003){ref-type="table"}.

###### 

Patients' characteristics

  Patient study number   Age (yr) at time of treatment   Gender   OAR               Primary tumor diagnosis          CTV volume (ccm)   Number *(n)* of balloon catheters
  ---------------------- ------------------------------- -------- ----------------- -------------------------------- ------------------ -----------------------------------
  1                      78                              Male     Stomach           Colorectal cancer                23.75              1
  2                      68                              Male     Stomach           Gastrointestinal stromal tumor   3.34               1
  3                      44                              Female   Duodenum          Leiomyosarcoma                   3.74               1
  4                      67                              Male     Stomach           Colorectal cancer                191.7              2
  5                      57                              Female   Stomach           Colorectal cancer                143.3              1
  6                      63                              Male     Large intestine   Renal cell cancer                22.3               1
  7                      54                              Female   Stomach           Colorectal cancer                87.95              2
  8                      64                              Female   Stomach           Cholangiocellular carcinoma      336.0              2
  9                      69                              Male     Stomach           Cholangiocellular carcinoma      10.3               1
  10                     77                              Male     Stomach           Hepatocellular cancer            10.36              1
  11                     70                              Male     Duodenum          Cholangiocellular carcinoma      62.7               1
  12                     74                              Female   Stomach           Colorectal cancer                40.68              2
  13                     69                              Female   Stomach           Colorectal cancer                18.75              1
  14                     48                              Female   Stomach           Pancreatic cancer                31.48              1
  15                     56                              Female   Stomach           Colorectal cancer                134.0              2
  16                     38                              Female   Stomach           Breast cancer                    3.54               1
  17                     73                              Male     Stomach           Gastrointestinal stromal tumor   32.35              1
  18                     74                              Male     Stomach           Cancer of unknown primary        9.37               1
  19                     46                              Female   Stomach           Breast cancer                    43.76              1
  20                     71                              Female   Stomach           Colorectal cancer                28.81              1
  21                     75                              Female   Stomach           Colorectal cancer                101.6              1
  22                     80                              Male     Stomach           Colorectal cancer                135.2              1
  23                     84                              Female   Stomach           Hepatocellular cancer            1.7                1
  24                     56                              Female   Stomach           Cholangiocellular carcinoma      2.96               1
  25                     60                              Male     Stomach           Colorectal Cancer                50.54              1
  26                     85                              Male     Stomach           Colorectal Cancer                74.0               1
  27                     47                              Male     Stomach           Colorectal cancer                9.3                1
  28                     74                              Female   Stomach           Gallbladder cancer               3.1                1
  29                     70                              Female   Stomach           Cancer of unknown primary        35.53              2
  30                     62                              Male     Stomach           Hepatocellular cancer            12.3               1
  31                     71                              Female   Stomach           Colorectal cancer                35.42              1

Application time for the whole implant depended on the number of inserted BT catheters and additional balloons. Median application time was 12.5 min (range, 7.5-30 min).

Organs at risk (stomach/duodenum, large intestine) D~1cc~ {#sec3.2}
---------------------------------------------------------

D~1cc~ of the OAR with balloon (mean, 12 Gy; deviation, 8.9 to 16.5 Gy; median, 13.5 Gy; IQR, 11.2 to 14.0 Gy) were significantly (*p* \< 0.001) lower compared to virtual anticipated OAR without a balloon (mean, 16 Gy; deviation, 11.1 to 25.1 Gy; median, 15.5 Gy; IQR, 14.3 to 16.7 Gy; [Figure 3A](#f0003){ref-type="fig"}). The corresponding median relative difference was --16.3% (IQR, --23.2 to --8.9%), ranging from --57.3% to --0.7% ([Table 4](#t0004){ref-type="table"}). [Figures 3A](#f0003){ref-type="fig"} and [3B](#f0003){ref-type="fig"} shows the correlation of D~1cc~ with and without a balloon, with a Spearman's correlation coefficient of 0.36 (*p* = 0.049). Comparing both methods with Bland-Altman, analysis revealed 95% limits of agreement of --9.6 Gy to 2.9 Gy, with a mean of --3.4 Gy ([Figure 3C](#f0003){ref-type="fig"}).

###### 

Statistics: organ at risk (OAR) D~1cc~ with and without a balloon as well as absolute and relative differences

  Parameter           OAR without balloon D~1cc~ (Gy)   OAR with balloon D~1cc~ (Gy)   Difference absolute (Gy)   Difference relative (%)
  ------------------- --------------------------------- ------------------------------ -------------------------- -------------------------
  Mean                16.0                              12.6                           --3.4                      --19.4
  SD                  3.2                               2.0                            3.1                        14.5
  Median              15.5                              13.5                           --2.5                      --16.3
  25^th^ percentile   14.3                              11.2                           --3.9                      --23.2
  75^th^ percentile   16.7                              14.0                           --1.4                      --8.9
  Minimum             11.1                              8.9                            --12.1                     --57.3
  Maximum             25.1                              16.5                           --0.1                      --0.7

![Boxplots (**A**), correlation (**B**), and Bland-Altmanplot (**C**) of D1cc with and without a balloon](JCB-11-36507-g003){#f0003}

Acute side effects and late morbidity {#sec3.3}
-------------------------------------

The additional balloon catheter was tolerated very well by all patients. Serious acute complications (e.g., bleeding) did not occur in any case. During the further course, 4 late complications in 3 patients (1 × abscess, 2 × gastric ulcers, 1 × non-classic radiation-induced liver disease \[RILD\]) were observed. Complications are described in detail in [Table 5](#t0005){ref-type="table"}.

###### 

Side effects

  Acute and late side effects according to CTCAE[^\#^](#tf5-1){ref-type="table-fn"} v. 4.03 \[[@cit0001]-[@cit0005]\]   Number of cases (*n*/%)   Patient study number   Treatment/outcome                   Interval between iBT and side effect
  --------------------------------------------------------------------------------------------------------------------- ------------------------- ---------------------- ----------------------------------- ---------------------------------------------
  Temporarily increase of bilirubin \[°1\]                                                                              1/3                       7                      No treatment/resolved               24 h
  Shivering \[°1\>\]                                                                                                    1/3                       15                     No treatment/resolved               1 h
  Nausea/vomiting \[°2\]                                                                                                2/6                       29                     Antiemetic drugs/ resolved          1 h
  Abscess \[°3\]                                                                                                        1/3                       20                     Drainage and antibiotics/resolved   8 weeks
  Non classic RILD[^\#\#^](#tf5-2){ref-type="table-fn"} (previous SIRT[\*](#tf5-3){ref-type="table-fn"}) \[°3\]         1/3                       7                      Ursodeoxycholic acid/resolved       12 weeks (18 weeks after radioembolization)
  Ulcus ventriculi[\*\*](#tf5-4){ref-type="table-fn"} \[°4\]                                                            1/3                       20                     Gastrectomy/resolved                14 weeks
  Ulcus ventriculi[\*\*\*](#tf5-5){ref-type="table-fn"} \[°5\]                                                          1/3                       11                     Gastrectomy/death                   15 weeks

common terminology criteria for adverse events

radiation-induced liver disease (RILD)

selective interne radiotherapy (SIRT)

patient with significantly increased cumulative exposition of gastric mucosa

patient with pre-existing chronic gastritis, long-term avastin-based and/or anticoagulation treatment, severe diabetes mellitus

Thus, formally the rate of significant late effects was 12.9% (\> 2) and 6.45% (\> 3), respectively. Of these, only in one case (3.22%, patient no. 20) a severe adverse event (SAE) can be suspected due to repeated radiation exposure of the gastric mucosa. Patient no. 11 suffered from diabetes mellitus and pre-existing chronic gastritis, and received long-term treatment with Avastin^®^ (Bevacizumab, Roche Pharma AG, Grenzach-Wyhlen, Germany) and anticoagulation, whereas patient no. 7 underwent a radio-embolization 18 weeks prior to RILD.

Discussion {#sec4}
==========

The data of this study demonstrate that the interventional application of one or two balloon catheter(s) into the connective tissue layer between the hepatic capsule and adjacent OAR generates a distance between subcapsular tumor lesion of the liver and OAR, resulting in a significant median reduction of dosage exposition of the adjacent OAR of about 16%. This effect enlarges the therapeutic "window" and consecutively, the CTV can be treated with a higher, thus presumably more efficient irradiation dose.

The current ESMO guideline for the treatment of metastatic colorectal cancer (CRC) \[[@cit0008]\] indicates the growing acceptance of minimally invasive methods for the treatment of oligo-metastases. The so-called "toolbox of minimally invasive methods" is particularly important because a significant proportion of patients with oligo-metastases are not resectable for various reasons \[[@cit0022]\]. However, in addition to the indisputable role of systemic treatment \[[@cit0023]\], local control is the key to potentially sustained improvement in the overall prognosis.

Modern irradiation techniques (e.g., stereotactic body radiotherapy \[SBRT\], iBT) enable precise application of very high single doses. In this regard, in addition to the tumor cell destruction mechanisms based on DNA damage, further effective radiobiological effects can be initiated \[[@cit0024],[@cit0025]\]. Though, even the most accurate dose application can be limited by the proximity of sensitive OAR. Chang *et al*. \[[@cit0026]\] reported a rate of ≥ 3 toxicity of 10% (mainly gastrointestinal \[GI\] ulceration) after 25 Gy single fraction SBRT for unresectable pancreatic adenocarcinoma, within adjacent stomach and further GI structures.

The concept of simultaneously integrated protection (SIP) could be a conceivable strategy to avoid high doses to an OAR \[[@cit0027]\]. Whether this is associated with an increased rate of local recurrences is yet to be seen. This question is currently being examined by a prospective clinical study. Therefore, the possibility of increasing distance of the CTV to surrounding OAR appears promising.

In recent years, various groups \[[@cit0028],[@cit0029],[@cit0030]\] have tested feasibility, safety, and application effect of absorbable polyethylene glycol (PEG) to increase the distance between the prostate and the rectal wall. In fact, by applying PEG, a dosimetrically effective distancing can be achieved.

Thus, higher irradiation doses in patients with prostate cancer can be accomplished without an increased risk of chronic side effects onto the rectal wall. Considering this successful principle of distancing, the analysis presented here verified the feasibility, tolerability, safety, and efficacy of a balloon catheter-based approach.

As a limitation, direct comparison of both approaches, with regard to acute side effects and late toxicities is difficult, since the affected OAR within the pelvis region on one hand and the abdominal cavity on the other have different tolerance doses and, moreover, the total and single doses of the irradiation concepts are not comparable.

In addition, in recent years, numerous studies have been published regarding interstitial brachytherapy of the liver \[[@cit0012],[@cit0013],[@cit0030],[@cit0031],[@cit0032],[@cit0033],[@cit0034],[@cit0035],[@cit0036]\]. The rate of side effects ≥ 3 listed in these studies was approximately 5%.

In contrast, the rate of late toxicities ≥ 3 (12.9%) in this study appears to be higher in comparison to the cited studies. Can one or two additionally applied balloon catheter(s) cause this difference? This is rather unlikely because in the affected patients, the pre-treatment modes (selective internal radiotherapy, surgical procedures, chemotherapy, repeated irradiation) as well as severe co-morbidities (insulin-dependent diabetes mellitus, chronic gastritis etc.) must be taken into consideration. Moreover, the intraoperative situs of the second (gastrectomized) patient (no. 11) also showed a recurrent liver metastasis, which had infiltrated and damaged a large area of the wall of the reconstructed upper GI tract.

Thus, the iBT (plus balloon)-related complication rate summarizing all side effects ≥ 3 (according to CTCAE v. 4.0) would be formally 3% (patient no. 20 with ulcer 4).

A further limitation of the study is the moderate number of cases and the retrospective and monocentric character of the analysis. In addition, the balloon catheters used are not optimal because they cannot distance the adjacent OARs in large space, only in very circumscribed areas. However, as far as known, there is currently no report on increasing the distance between tumor lesion and adjacent OAR by balloon catheter(s).

For optimization, reusable balloon catheters should be designed to be inflated and deflated when in position. In order to avoid selection bias, the results of this analysis should be examined in a prospective, possibly multicenter study.

Conclusions {#sec5}
===========

Insertion of balloon catheters to increase the distance between subcapsular liver malignomas and adjacent OAR is feasible, low-risk (i.e., safe), and minimally invasive to significantly reduce the radiation dose exposure of the affected OAR due to iBT. This distancing of the adjacent OAR allows a higher D~100~ value of the CTV, therefore allowing for more efficient local control. Consequently, efficacy and sustainability of radio-ablative procedures can be increased.

During a short-term single-fraction iBT, an additional balloon catheter is well tolerated. Whether the insertion of such a catheter would also be possible for a longer period of several days within a fractional SBRT (several days) is currently still not investigated by a systematic study approach.

Thus, the insertion of a balloon catheter in cases with close-fitting OAR, which also overcomes the limitations of percutaneous, non-interventional SBRT, should be further discussed and more extensively proven as an additional option.

Addendum {#sec6}
========
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